Sirukumab meets both co-primary endpoints in rheumatoid arthritis study
A phase III clinical trial evaluating sirukumab in adult patients with moderately to severely active rheumatoid arthritis (RA) met both co-primary endpoints.Sirukumab is being co-developed by GlaxoSmithKline (GSK) and Janssen Biologics in a partnership that startesd in December 2011.It is a human monoclonal IgG kappa antibody that binds to interleukin-6 (IL-6), a cytokine that plays an important role in autoimmune conditions.The SIRROUND-D study randomized 1,670 patients with moderately to severely active RA who had an inadequate response to disease-modifying antirheumatic drugs.Patients received either sirukumab 50mg every 4 weeks, sirukumab 100mg every 2 weeks or placebo.Results from the study demonstrated that patients treated with sirukumab experienced significantly less joint destruction than placebo (p<0.001) from baseline to week 52 as measured by a method called Sharp van der Heijde Score which is used to measure joint damage observed in X-ray images.There was a minimum 20% improvement in RA symptoms for more than half of patients by week 16.All major secondary endpoints were also met. Regulatory applications for sirukumab for RA are expected in the third quarter of this year.Sirukumab has not been approved as a treatment for any indication anywhere in the world.The agreement between GSK and Janssen gives both companies the option to evaluate sirukumab for other indications beyond RA.Last November, GSK initiated a phase III study of sirukumab for patients with Giant Cell Arteritis.
Published 10 June 2016
FDA Offers Advice on NDAs for Postoperative Local Anesthetics
Sponsors developing long-acting local postoperative anesthetics should consider including novel, clinically meaningful endpoints in their trial design, the FDA has said in new draft guidance. ...
Sarepta slides as FDA about-turn on panel clouds gene therapy approval path
Shares of Sarepta Therapeutics Inc slumped as much as 21% on Friday on uncertainty over its gene therapy for Duchenne muscular dystrophy after the U.S. health regulator reversed its decision on a p...
Amgen to cut 450 jobs in second round of layoffs this year
(Reuters) - Amgen Inc said on Thursday it would cut 450 jobs, or less than 2% of its workforce, making it the company's second round of layoffs this year amid intensifying pressure on drug prices ...